Boston Scientific Corp. BSX, -1.90% posted better-than-expected third-quarter earnings early Thursday and raised its full-year guidance. The medical technology company had net income of $505 million, or 34 cents a share, for the quarter, up from $174 million, or 12 cents a share, in the year-earlier period.
Adjusted per-share earnings came to 50 cents, ahead of the 48 cent FactSet consensus. Sales rose to $3.527 billion from $3.170 billion a year ago, also ahead of the $3.477 billion FactSet consensus. The company now expects full-year adjusted EPS of $1.99 to $2.02, while FactSet is expecting $2.00. It expects full-year sales to rise 11%. The stock has gained 8% in the year to date, while the S&P 500 SPX, -1.43% has gained 9%.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Penske Automotive’s stock slides premarket after profit miss amid ‘challenging’ used car marketCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Weiterlesen »